Twitter Beğeni Hilesi

Personalized ctDNA for monitoring disease in HNSCC -- out today in Clinical Cancer Research and presented at ASCO Best of ASCO Dana-Farber Dana-Farber News Natera 👀🧬🧪🧐 aacrjournals.org/clincancerres/…

nature.com/articles/s4159… fantastic innovation for refractory #colorectalcancer ⁦Dana-Farber⁩ ⁦Dana-Farber's Young-Onset Colorectal Cancer Center⁩ ⁦Dana-Farber News⁩ ⁦BIDMC⁩ ⁦Anthony El-Khoueiry⁩ ⁦Dr. Marwan G. Fakih⁩ ⁦Bruno Bockorny MD FACP⁩ ⁦Agenus⁩

Thrilled to see my good friend Bruno Bastos MD being recognized on this list! Well deserved!!! #BestProstateCancerDocs newsweek.com/rankings/ameri…

Congratulations Jake! I am very excited for you. This will be the first of many grants!

Published today! We found that cancer cells adapting to drug treatments don't simply switch from a sensitive to resistant state; instead there's a ‘resistance continuum’ of resistant phenotypes with epigenetically reprogrammed states. 🧵⬇️ nature.com/articles/s4158… Gustavo França

New in @sciencemagazine! Our study reveals how mutant IDH1 inhibition activates tumor immunity by inducing dsDNA sensing. Read more: science.org/doi/10.1126/sc… #CancerResearch #Cholangiocarcinoma #IDH1 1/n

Publication alert 📢 We use "#multiomics machine learning to study host-#microbiome interactions in early-onset vs average-onset colorectal #cancer" Alok Khorana, MD Suneel Kamath MD Naseer sangwan Cleveland Clinic MD Springer Nature npj Journals nature.com/articles/s4169…

TP53: - Discovered 45 years ago, most cited gene all time - No therapies - 500 million people currently living will die of TP53 mutant cancers without new therapies Our Preprint: - A general strategy for TP53 missense mutant cancers (majority) with prototype small molecules

Useful literature review from Richard Dunne, MD Wilmot Cancer Institute & colleagues on #cachexia incidence & impact on survival in #PancreaticCancer & #ColorectalCancer onlinelibrary.wiley.com/doi/10.1002/jc… Pancreatic cancer data below across reviewed studies. Important citation for cachexia researchers.

Patients who want to directly contribute to cancer research face several barriers. Our Journal of Clinical Oncology commentary, co-authored by leaders of the PE-CGS National Cancer Institute, offers solutions to address them: bit.ly/PECGS-JCO Dana-Farber Dana-Farber News Broad Institute Count Me In

Congratulations to Harsh Singh and Dana-Farber team for getting this data out. CAPOX + Trastuzumab + Bevacizumab in frontline HER2+ gastroesophageal. Nature Communications James Cleary Ronan Kelly and others rdcu.be/dQvh4 -- full paper doi.org/10.1038/s41467…

Our study on sex differences in Xp11 translocation renal cell carcinoma is out Cell! We ascribe a genetic basis to the female bias in tRCC, which is driven by a translocation of the TFE3 gene on the X chromosome. w Zhang lab @danafarbernews bit.ly/4dtpNtP 🧵1/

Join us! My lab UMass Chan Medical School is seeking postdocs and research associates who are passionate about how changes in metabolism and epigenetics contribute to cancer development and immune system evasion. DM me for a chat and apply at ummsjobs.com/job/10593/ (postdoc position)

🚨🚨Hot off the press NEJM In a randomized Ph II Ponsegromab, an anti-GDF15 mAB, increased weight gain, overall physical activity and reduced cachexia symptoms in patients with #cachexia and ⬆️ GDF-15 nejm.org/doi/full/10.10…

👑Presidential #ESMO24 -Practice changing trials ESMO - Eur. Oncology ➡️POD1UM-303 / InterAACT-2 Retifanlimab plus carboplatin-paclitaxel in 1L of advanced anal SCC ✅mPFS: 9.30 vs 7.39 mo; HR: 0.63 [0.47, 0.84]; P=0.0006) ➡️90% of patients CPS >=1 OncoAlert #cancer #oncology #MedX

Retifanlimab + carboplatin-paclitaxel in 1L squamous cell carcinoma of the anal canal #ESMO24 🔎POD1UM-303/InterAACT 2 👉mPFS 7.4 vs 9.4 mo 👉mOS 23 vs 29 mo 👉Limited impact of n cross over (45%) 🧐Practice-changing trial 👏excellent discussion by D. Modest ESMO - Eur. Oncology

#FIC ! #KRAS #G12D protein #degrader evaluated in heavily treated PDAC in 3L+ setting. Responses in non-chemotherapeutic backbone in this setting is not expected so this very encouraging! Thanks for sharing! #ESMO24 ESMO - Eur. Oncology MSK Department of Medicine MSKCC Center for Pancreatic Cancer Research

Fantastic Rising Star Keynote by Joe Mancias Mancias Lab at #AACRpan24 highlighting the role of autophagy in PDAC. Hale Family Center For Pancreatic Cancer Research

🔥Presidential Symposium III: Eyes to the future🔥 AMG 193: A MTA-cooperative PRMT5 inhibitor, in MTAP-deleted solid tumors 🔎 Phs I 👉very interesting MOA 👉responses across multiple tumor types 🧐🎯MTAP-deleted tumours safe & feasible, more studies ongoing ESMO - Eur. Oncology

🚨#POLAR maintenance: Cohort A HRD by BRCA2, PALB2, BRCA1 pembro + olaparib (no chemo) ORR 35%, 6M PFS rate 62% [47-82] maturing 3YOS rate 58% & rare outlier pts in Cohorts B&C. Ongoing deep 🔬science Eileen M O’Reilly MSKCC Center for Pancreatic Cancer Research Memorial Sloan Kettering Cancer Center #PancreaticCancer #ESMO24 ESMO - Eur. Oncology